Trials / Unknown
UnknownNCT04467125
Nexplanon Removal: Subcutaneous vs. Topical Lidocaine
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Augusta University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A randomized trial of using EMLA cream for anesthesia to remove Nexplanon versus the standard route of subcutaneous lidocaine for anesthesia. Primary endpoints are pain during procedure and time to removal.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eutectic Lidocaine Prilocaine | Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed. |
| DRUG | Subcutaneous Lidocaine | Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider. |
Timeline
- Start date
- 2020-01-06
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
- First posted
- 2020-07-10
- Last updated
- 2020-07-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04467125. Inclusion in this directory is not an endorsement.